Dong H, et al. - Given that circulating tumor cells (CTCs) represent significant clinical indicators of metastatic progression and treatment effectiveness, researchers sought to develop a new patient-derived CTC model to better predict these effects. For this purpose, they obtained blood from 10 patients with epithelial ovarian cancer (EOC) and one pancreatic cancer patient and reported on the isolation and characterization of the invasive population of CTCs (iCTCs) based on the avidity of tumor cells toward an artificial collagen-based adhesion matrix (CAM) vs tumor progenitor (TP) cells isolated from tumor cell lines, tumors and ascites from EOC patients. In this study, using the attenuated formation of iCTCs and micrometastases via RNAi, peptides, and monoclonal antibodies against seprase, iCTCs were identified as new therapeutic targets for blocking metastasis.